<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2105</journal-id><journal-id journal-id-type="pmc-domain">cancers</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11049132</article-id><article-id pub-id-type="pmcid-ver">PMC11049132.1</article-id><article-id pub-id-type="pmcaid">11049132</article-id><article-id pub-id-type="pmcaiid">11049132</article-id><article-id pub-id-type="pmid">38672676</article-id><article-id pub-id-type="doi">10.3390/cancers16081594</article-id><article-id pub-id-type="publisher-id">cancers-16-01594</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Endovascular Applications for the Management of High-Grade Gliomas in the Modern Era</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6179-8461</contrib-id><name name-style="western"><surname>Kappel</surname><given-names initials="AD">Ari D.</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af2-cancers-16-01594" ref-type="aff">2</xref><xref rid="fn1-cancers-16-01594" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jha</surname><given-names initials="R">Rohan</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="fn1-cancers-16-01594" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guggilapu</surname><given-names initials="S">Saibaba</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="WJ">William J.</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af3-cancers-16-01594" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feroze</surname><given-names initials="AH">Abdullah H.</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af2-cancers-16-01594" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dmytriw</surname><given-names initials="AA">Adam A.</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af3-cancers-16-01594" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vicenty-Padilla</surname><given-names initials="J">Juan</given-names></name><xref rid="af4-cancers-16-01594" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-1845-263X</contrib-id><name name-style="western"><surname>Alcedo Guardia</surname><given-names initials="RE">Rodolfo E.</given-names></name><xref rid="af4-cancers-16-01594" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3471-0575</contrib-id><name name-style="western"><surname>Gessler</surname><given-names initials="FA">Florian A.</given-names></name><xref rid="af5-cancers-16-01594" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="NJ">Nirav J.</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af2-cancers-16-01594" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2641-6496</contrib-id><name name-style="western"><surname>Du</surname><given-names initials="R">Rose</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af2-cancers-16-01594" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3634-4692</contrib-id><name name-style="western"><surname>See</surname><given-names initials="AP">Alfred P.</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af6-cancers-16-01594" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5034-2963</contrib-id><name name-style="western"><surname>Peruzzi</surname><given-names initials="PP">Pier Paolo</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af2-cancers-16-01594" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aziz-Sultan</surname><given-names initials="MA">Mohammad A.</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af2-cancers-16-01594" ref-type="aff">2</xref><xref rid="c1-cancers-16-01594" ref-type="corresp">*</xref><xref rid="fn2-cancers-16-01594" ref-type="author-notes">&#8225;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7814-3867</contrib-id><name name-style="western"><surname>Bernstock</surname><given-names initials="JD">Joshua D.</given-names></name><xref rid="af1-cancers-16-01594" ref-type="aff">1</xref><xref rid="af2-cancers-16-01594" ref-type="aff">2</xref><xref rid="c1-cancers-16-01594" ref-type="corresp">*</xref><xref rid="fn2-cancers-16-01594" ref-type="author-notes">&#8225;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Lindstr&#246;m</surname><given-names initials="MS">Mikael S.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-cancers-16-01594"><label>1</label>Harvard Medical School, Boston, MA 02115, USA; <email>akappel@bwh.harvard.edu</email> (A.D.K.); <email>g.saibaba13@gmail.com</email> (S.G.); <email>rdu@bwh.harvard.edu</email> (R.D.); <email>pokmeng.see@childrens.harvard.edu</email> (A.P.S.); </aff><aff id="af2-cancers-16-01594"><label>2</label>Department of Neurosurgery, Brigham and Women&#8217;s Hospital, Boston, MA 02115, USA</aff><aff id="af3-cancers-16-01594"><label>3</label>Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA</aff><aff id="af4-cancers-16-01594"><label>4</label>Neurosurgery Section, School of Medicine University of Puerto Rico, Medical Sciences Campus, San Juan P.O. Box 365067, Puerto Rico<email>rodolfo.alcedo@upr.edu</email> (R.E.A.G.)</aff><aff id="af5-cancers-16-01594"><label>5</label>Department of Neurosurgery, Rostock University Hospital, 18057 Rostock, Germany</aff><aff id="af6-cancers-16-01594"><label>6</label>Department of Neurosurgery, Boston Children&#8217;s Hospital, Boston, MA 02115, USA</aff><author-notes><corresp id="c1-cancers-16-01594"><label>*</label>Correspondence: <email>asultan@bwh.harvard.edu</email> (M.A.A.-S.); <email>jbernstock@bwh.harvard.edu</email> (J.D.B.)</corresp><fn id="fn1-cancers-16-01594"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn><fn id="fn2-cancers-16-01594"><label>&#8225;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2024</year></pub-date><volume>16</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">461128</issue-id><elocation-id>1594</elocation-id><history><date date-type="received"><day>03</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-28 12:25:23.747"><day>28</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cancers-16-01594.pdf"/><abstract><sec><title>Simple Summary</title><p>This review discusses new treatments for high-grade gliomas (HGGs), aggressive brain tumors that are difficult to treat. It focuses on emerging endovascular therapies and future directions. Endovascular methods use catheters in a minimally invasive manner to deliver drugs to the tumor through blood vessels in the brain while limiting harm to the rest of the body. Super-selective intra-arterial cerebral infusion (SSIACI) is an endovascular technique that aims to deliver treatments directly to the tumor by reaching the closest blood vessels supplying the tumor. Many challenges remain to fully adopting these techniques in clinical practice, including the ability of drugs to cross the blood&#8211;brain barrier, and getting the drugs to stay in the tumor for long enough before they are washed out by normal blood in the brain. Focused ultrasound and hyperosmotic disruption are techniques which might help with these challenges. Researchers are investigating new drugs beyond traditional chemotherapies, such as radiation embedded molecules and immune-based therapies. Future directions include monitoring tumors with endovascular sampling; changing drug formulations to stay in the tumor longer; and investigating other treatments, like radioembolization. These endovascular strategies have the potential to improve how HGGs are treated, but more research is needed to ensure they work well and are safe for patients.</p></sec><sec><title>Abstract</title><p>High-grade gliomas (HGGs) have a poor prognosis and are difficult to treat. This review examines the evolving landscape of endovascular therapies for HGGs. Recent advances in endovascular catheter technology and delivery methods allow for super-selective intra-arterial cerebral infusion (SSIACI) with increasing precision. This treatment modality may offer the ability to deliver anti-tumoral therapies directly to tumor regions while minimizing systemic toxicity. However, challenges persist, including blood&#8211;brain barrier (BBB) penetration, hemodynamic complexities, and drug&#8211;tumor residence time. Innovative adjunct techniques, such as focused ultrasound (FUS) and hyperosmotic disruption, may facilitate BBB disruption and enhance drug penetration. However, hemodynamic factors that limit drug residence time remain a limitation. Expanding therapeutic options beyond chemotherapy, including radiotherapy and immunobiologics, may motivate future investigations. While preclinical and clinical studies demonstrate moderate efficacy, larger randomized trials are needed to validate the clinical benefits. Additionally, future directions may involve endovascular sampling for peri-tumoral surveillance; changes in drug formulations to prolong residence time; and the exploration of non-pharmaceutical therapies, like radioembolization and photodynamic therapy. Endovascular strategies hold immense potential in reshaping HGG treatment paradigms, offering targeted and minimally invasive approaches. However, overcoming technical challenges and validating clinical efficacy remain paramount for translating these advancements into clinical care.</p></sec></abstract><kwd-group><kwd>endovascular</kwd><kwd>high-grade glioma</kwd><kwd>glioblastoma</kwd><kwd>interventional neuroradiology</kwd><kwd>blood&#8211;brain barrier</kwd><kwd>focused ultrasound</kwd><kwd>future therapies</kwd><kwd>drug delivery</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-16-01594"><title>1. Introduction</title><p>The annual incidence of high-grade gliomas (HGGs) in the United States is estimated to be 3.19 cases per 100,000 individuals, with approximately 14,000 new cases each year [<xref rid="B1-cancers-16-01594" ref-type="bibr">1</xref>]. Glioblastoma (GBM), classified as a World Health Organization (WHO) grade 4 glioma, is the most prevalent malignant primary brain tumor [<xref rid="B2-cancers-16-01594" ref-type="bibr">2</xref>]. The prognosis for GBM remains poor, with a median overall survival of 15&#8211;18 months with a standard treatment regimen of surgery, radiation, and temozolomide [<xref rid="B3-cancers-16-01594" ref-type="bibr">3</xref>], and a 5-year survival rate of only 6.8% [<xref rid="B3-cancers-16-01594" ref-type="bibr">3</xref>,<xref rid="B4-cancers-16-01594" ref-type="bibr">4</xref>]. Despite substantial advancements in understanding of GBM molecular biology and the identification of new molecular drug targets [<xref rid="B5-cancers-16-01594" ref-type="bibr">5</xref>], progress in improving overall survival has remained limited [<xref rid="B3-cancers-16-01594" ref-type="bibr">3</xref>]. GBM invariably recurs and disseminates in all patients, and most of these recurrences occur locally [<xref rid="B6-cancers-16-01594" ref-type="bibr">6</xref>,<xref rid="B7-cancers-16-01594" ref-type="bibr">7</xref>]. Extensive areas of infiltration, necrosis, hemorrhage, and thrombosis within the tumor microenvironment collectively hinder the successful administration of therapeutic drugs, notwithstanding delivery limitations pertaining to the blood&#8211;brain barrier (BBB) itself [<xref rid="B8-cancers-16-01594" ref-type="bibr">8</xref>]. In response to these challenges, there is a burgeoning interest in local therapies directed to the tumor cavity [<xref rid="B9-cancers-16-01594" ref-type="bibr">9</xref>]. The current review focuses on the role of endovascular strategies for local treatment of HGGs to bypass the BBB and prevent local recurrence.</p><p>Endovascular treatment for high-grade gliomas (HGGs), including glioblastoma (GBM), was reported as early as the 1950s by Klopp et al. and French et al. [<xref rid="B10-cancers-16-01594" ref-type="bibr">10</xref>,<xref rid="B11-cancers-16-01594" ref-type="bibr">11</xref>]. The overarching objectives in treating HGG via intra-arterial (IA) chemotherapy is to identify therapeutic agents that can be delivered to the tumor and bypass the blood&#8211;brain barrier (BBB) in a reliable and controlled fashion, while minimizing both systemic and neurologic drug toxicity [<xref rid="B12-cancers-16-01594" ref-type="bibr">12</xref>]. IA drug administration offers the potential to achieve heightened pharmaceutical drug concentrations within specific tumor regions and increase the likelihood of inducing tumor response. Additionally, IA drug delivery mitigates the often considerable systemic toxicity associated with systemic drug delivery, thereby enabling the exploration of higher chemotherapeutic dosages [<xref rid="B13-cancers-16-01594" ref-type="bibr">13</xref>]. These potential benefits have only become more evident with improved endovascular catheter technology allowing for increased specificity in drug delivery with super-selective intra-arterial cerebral infusion (SSIACI) [<xref rid="B12-cancers-16-01594" ref-type="bibr">12</xref>]. Despite technological advances and more targeted infusion, studies have failed to show a significant benefit of IA chemotherapy [<xref rid="B14-cancers-16-01594" ref-type="bibr">14</xref>]. We conducted an updated review of the literature to highlight recent advancements and to provide an updated view of the two major components and areas of innovation in endovascular therapy for HGGs&#8212;the therapy being delivered and the method of delivery.</p></sec><sec id="sec2-cancers-16-01594"><title>2. Delivery Methods</title><p>The development of smaller, more navigable catheters has allowed for the development of increasingly targeted delivery, ushering in the era of selective intra-arterial cerebral injection (SIACI) and super-selective intra-arterial cerebral injection (SSIACI). Advancements in catheter technology have been largely driven by cerebrovascular pathologies and compatibility testing between various chemotherapies, and cell therapies with the catheter materials must be considered and may occasionally pose a challenge [<xref rid="B15-cancers-16-01594" ref-type="bibr">15</xref>]. The advantages of super-selective IA delivery include the ability to deliver high drug doses with decreased systemic effects, while limitations include difficulty penetrating the BBB, challenging hemodynamics and pharmacokinetics, off-target effects, and a low drug residence time (<xref rid="cancers-16-01594-f001" ref-type="fig">Figure 1</xref>).</p><sec id="sec2dot1-cancers-16-01594"><title>2.1. Super-Selective Intra-Arterial Cerebral Infusions</title><p>Early non-selective administration of therapeutic agents via IA routes such as carotid or vertebral arteries encountered significant challenges, including profound neurotoxicity, e.g., severe leukoencephalopathy, blindness, and cerebral necrosis [<xref rid="B16-cancers-16-01594" ref-type="bibr">16</xref>]. Ototoxicity has been described with IA cisplatin administration, but fewer patients who received IA cisplatin required hearing aids compared to patients who received IV cisplatin [<xref rid="B17-cancers-16-01594" ref-type="bibr">17</xref>]. The application of advanced endovascular techniques used in the treatment of cerebrovascular diseases adapted to the super-selective delivery of therapeutic agents for brain tumors has provided technical improvements [<xref rid="B18-cancers-16-01594" ref-type="bibr">18</xref>].</p><p>Using modern microcatheters, therapeutic agents can be selectively delivered to distal arterial pedicles directly supplying the tumor. Modern neurointerventional techniques involve triaxial endovascular systems [<xref rid="B19-cancers-16-01594" ref-type="bibr">19</xref>] with larger bore (6F to 8F) guide catheters and smaller intermediate and microcatheters telescoping from the femoral artery or radial artery to the distal cerebral vasculature [<xref rid="B20-cancers-16-01594" ref-type="bibr">20</xref>]. These techniques may help to safely minimize the exposure of normal brain parenchyma to the infused agent by achieving distal access close to the arterial supply of the tumor and avoiding more proximal arterial infusions, such as traditional internal carotid artery or vertebral artery infusions, which may expose more normal brains to neurotoxic chemotherapeutics [<xref rid="B21-cancers-16-01594" ref-type="bibr">21</xref>,<xref rid="B22-cancers-16-01594" ref-type="bibr">22</xref>]. Drug infusions may be performed manually via hand injections over a period of minutes, with intra-arterial balloons, side ports, or pulsatile injections [<xref rid="B21-cancers-16-01594" ref-type="bibr">21</xref>]. This method may restrict the volume of distribution (Vd) of a given agent to the specific pathology and its surrounding vascularized tissues. As a result, drugs may accumulate locally within the tumor, may be delivered at higher doses, and may reduce the systemic levels and subsequent toxicity of a given drug. This approach may be particularly suitable for primary brain malignancies, as they typically exhibit local recurrence without widespread metastasis [<xref rid="B12-cancers-16-01594" ref-type="bibr">12</xref>]. SSIACI has demonstrated efficacy particularly in the context of retinoblastoma [<xref rid="B23-cancers-16-01594" ref-type="bibr">23</xref>,<xref rid="B24-cancers-16-01594" ref-type="bibr">24</xref>] but has also been evaluated for use in GBM [<xref rid="B15-cancers-16-01594" ref-type="bibr">15</xref>]. MR perfusion imaging co-registered to cone beam CT to select and monitor IA infusion of chemotherapy has been described as perfusion-guided endovascular super-selective intra-arterial chemotherapy infusion (PG-ESIACI) [<xref rid="B25-cancers-16-01594" ref-type="bibr">25</xref>]. This technology allows for optimal vessel selection and the monitoring of chemotherapy delivery through the BBB into the tumor bed, setting a new precedent for locoregional targeting of chemotherapy [<xref rid="B21-cancers-16-01594" ref-type="bibr">21</xref>,<xref rid="B22-cancers-16-01594" ref-type="bibr">22</xref>].</p><p>The uniform delivery of intra-arterially administered drugs to brain tissues is not guaranteed [<xref rid="B26-cancers-16-01594" ref-type="bibr">26</xref>,<xref rid="B27-cancers-16-01594" ref-type="bibr">27</xref>]. The phenomenon known as &#8220;streaming&#8221; may result in heterogeneous drug delivery during IA infusion as a result of the flow dynamics, layering of blood in arteries, and insufficient mixing, which may potentially limit treatment effect [<xref rid="B22-cancers-16-01594" ref-type="bibr">22</xref>,<xref rid="B28-cancers-16-01594" ref-type="bibr">28</xref>]. Strategies to mitigate streaming include large-volume injections exceeding 20% of the background blood flow rate, timing injections to occur during diastole, and using catheters with side ports [<xref rid="B22-cancers-16-01594" ref-type="bibr">22</xref>,<xref rid="B29-cancers-16-01594" ref-type="bibr">29</xref>]. Spatial dose fractionation algorithms have also emerged, which calculate the necessary agent dose based on vascular perfusion in cerebral vascular territories, ensuring that the dose is proportional to the regional blood flow [<xref rid="B26-cancers-16-01594" ref-type="bibr">26</xref>].</p><p>In the context of GBM, chemotherapy concentration increases by 20-fold when infused intra-arterially compared to the intravenous (IV) route, translating into a substantial 3&#8211;5.5-fold increase in intratumor chemotherapy concentrations due to the highly vascularized nature of most GBM [<xref rid="B30-cancers-16-01594" ref-type="bibr">30</xref>]. Moreover, the combination of SSIACI with blood&#8211;brain barrier (BBB) disruption for treating malignant gliomas can yield local concentrations of chemotherapeutics in brain tumors over 300 times higher than IV delivery, depending on infusion method, rate, and duration [<xref rid="B31-cancers-16-01594" ref-type="bibr">31</xref>]. Although the application of selective or super-selective terminology can vary from different reports, in general, SSIACI achieves high intratumoral drug concentrations when there is low regional blood flow, high regional drug extraction, rapid systemic clearance, and precise tissue concentration (i.e., achieved through pulsed or bolus dosing) [<xref rid="B32-cancers-16-01594" ref-type="bibr">32</xref>].</p></sec><sec id="sec2dot2-cancers-16-01594"><title>2.2. Blood&#8211;Brain Barrier Disruptors</title><p>The exposure of chemotherapeutic agents to tumor tissue is primarily hindered by the BBB. The BBB represents a complex interplay of endothelial cells, astrocytes, pericytes, basal lamina, extracellular matrix (ECM), smooth muscle cells, and neurons, collectively forming the neurovascular unit (NVU), which governs cerebral blood flow and regulates BBB function [<xref rid="B33-cancers-16-01594" ref-type="bibr">33</xref>]. Tight junctions, efflux pumps, and astrocyte podocytes in the BBB limit the passage of ionized molecules with molecular weights that exceed approximately 180 Da [<xref rid="B22-cancers-16-01594" ref-type="bibr">22</xref>,<xref rid="B34-cancers-16-01594" ref-type="bibr">34</xref>]. This poses a significant challenge to the delivery of various chemotherapeutic agents, and effective drug delivery methods to penetrate or bypass the BBB are required. Therefore, bypassing the BBB is a tantalizing approach to effectively delivering high doses of anti-tumoral drugs locally, while achieving effective doses without the systemic side effects.</p><p>There is limited BBB penetration by most anticancer drugs and chemotherapeutics [<xref rid="B35-cancers-16-01594" ref-type="bibr">35</xref>]. Temozolomide and topotecan have relatively high CSF/plasma ratios compared to other chemotherapeutics but are still on 20% [<xref rid="B36-cancers-16-01594" ref-type="bibr">36</xref>] and 32%, respectively [<xref rid="B37-cancers-16-01594" ref-type="bibr">37</xref>]. Most other commonly used chemotherapies have area under the curve (AUC)-CSF-to-AUC-plasma ratios of &lt;5%, including doxorubicin (&lt;5%) [<xref rid="B38-cancers-16-01594" ref-type="bibr">38</xref>], cisplatin (3%) [<xref rid="B39-cancers-16-01594" ref-type="bibr">39</xref>], carboplatin (2.6%) [<xref rid="B39-cancers-16-01594" ref-type="bibr">39</xref>], methotrexate (2.8%) [<xref rid="B40-cancers-16-01594" ref-type="bibr">40</xref>], and vincristine (0%) [<xref rid="B41-cancers-16-01594" ref-type="bibr">41</xref>].</p><p>Hyperosmotic disruption of the BBB is a commonly employed technique for BBB disruption [<xref rid="B35-cancers-16-01594" ref-type="bibr">35</xref>]. This strategy involves the infusion of a hypertonic solution, such as mannitol, into the cerebral arteries, thus establishing an osmotic gradient that induces the efflux of water from endothelial cells [<xref rid="B42-cancers-16-01594" ref-type="bibr">42</xref>]. Consequently, these cells shrink, and dehydration of endothelial cells interferes with tight junctions, resulting in the heightened permeability of the BBB [<xref rid="B43-cancers-16-01594" ref-type="bibr">43</xref>]. Notably, osmotic disruption can enhance the levels of successfully infused chemotherapeutic agents by as much as 90-fold [<xref rid="B22-cancers-16-01594" ref-type="bibr">22</xref>].</p><p>Focused ultrasound (FUS) has emerged as a promising method for achieving temporary and localized disruption of the BBB in a safe manner. This technique involves the use of low-power FUS, which can provide precise and transient focal disruption of the BBB. The technique employs microbubbles to facilitate the localized and temporary opening of the BBB, thereby allowing drugs to accumulate in the brain parenchyma. During this process, acoustic pressure from a transducer causes microbubbles to be pressed against the endothelial cell wall, inducing temporary and localized disruption of the BBB [<xref rid="B44-cancers-16-01594" ref-type="bibr">44</xref>]. FUS has demonstrated its capacity to safely deliver a wide range of therapeutic agents through the BBB in non-human models [<xref rid="B45-cancers-16-01594" ref-type="bibr">45</xref>]. These include brain-penetrating nanoparticles, 1,2-bis(2-chloroethyl)-1-nitrosurea, iron oxide magnetic particles conjugated to epirubicin, and gene-based therapy agents [<xref rid="B46-cancers-16-01594" ref-type="bibr">46</xref>,<xref rid="B47-cancers-16-01594" ref-type="bibr">47</xref>]. Even when drugs manage to penetrate the BBB, they often fail to achieve therapeutically effective local concentrations and frequently cannot attain the effective regional concentrations without inducing unacceptable systemic doses and associated toxicities. The deployment of SSIACI with biplane fluoroscopy combined with extracranial FUS equipment has not been implemented in practice, although extracranial applications of catheter-based ablative ultrasound have been reported with 6Fr devices [<xref rid="B48-cancers-16-01594" ref-type="bibr">48</xref>,<xref rid="B49-cancers-16-01594" ref-type="bibr">49</xref>]. The combination of an extracranial FUS system which can apply spatial targeting with SSIACI at varying levels of vascular selectivity may lead to clinically relevant BBB disruption in the future.</p><p>The combined approach of BBB breakdown and SSIACI could potentially yield significant survival improvements in patients with GBM. When compared to IV infusion, the combination of IA infusion with BBB permeabilization has been reported to result in a remarkable 320-fold-higher drug concentration [<xref rid="B30-cancers-16-01594" ref-type="bibr">30</xref>]. This combined strategy holds promise for enhancing the efficacy of drug delivery to brain tumors, particularly in the context of the treatment of HGGs.</p></sec><sec id="sec2dot3-cancers-16-01594"><title>2.3. Drug&#8211;Tumor Residence Time</title><p>Increasing the drug&#8211;tumor residence time is key to improving outcomes in HGG [<xref rid="B50-cancers-16-01594" ref-type="bibr">50</xref>]. A modification of the concept of drug&#8211;target residence time first introduced by Copeland and colleagues in 2006 [<xref rid="B51-cancers-16-01594" ref-type="bibr">51</xref>], drug&#8211;tumor residence time refers to the time a drug spends bound to the tumor in vivo. The concept of drug&#8211;tumor residence time avoids the limitations of in vitro assays that measure equilibrium binding metrics and drug-binding affinity and refers to the lifetime of the binary drug&#8211;target complex in vivo accounting for absorption, metabolism, and tissue distribution [<xref rid="B52-cancers-16-01594" ref-type="bibr">52</xref>]. Furthermore, drug&#8211;target residence time in vivo is defined by the inverse of the drug&#8211;target dissociation rate constant [<xref rid="B52-cancers-16-01594" ref-type="bibr">52</xref>]. Therefore, the longer a drug can remain bound to its target tumor and the lower the dissociation rate constant, the longer the drug&#8211;tumor residence time and the longer the anti-tumoral activity of the drug. It is not clear what the optimal drug&#8211;tumor residence time is for various drugs and different tumors; however, new drug formulations with nanoparticles and antibody tags, convection enhanced delivery methods, or continuous targeted infusions are strategies to increase the drug&#8211;tumor residence time and may be necessary to improve outcomes in HGG [<xref rid="B50-cancers-16-01594" ref-type="bibr">50</xref>]. Power et al., found that the delivery of alisertib was effective in the treatment of H3K27M-mutated tumors was only after direct administration over an extended 7-day period [<xref rid="B50-cancers-16-01594" ref-type="bibr">50</xref>]. New nanoparticle formulations and delivery methods may help improve drug&#8211;tumor residence time [<xref rid="B53-cancers-16-01594" ref-type="bibr">53</xref>]. In addition, drug&#8211;tumor residence time may modulate the rate of drug metabolism, hence affecting drug efficacy [<xref rid="B54-cancers-16-01594" ref-type="bibr">54</xref>]. Given the limitations of the streaming effects on drug residence time with the IA delivery of target therapeutics, new formulations of drugs may be necessary to enhance the efficacy of IA therapeutics for HGG.</p></sec><sec id="sec2dot4-cancers-16-01594"><title>2.4. Technical Considerations of Endovascular Therapeutics</title><p>As discussed so far, failures in effectively achieving therapeutic drug concentrations within the brain via IA therapy include BBB permeability, streaming effects and volume of distribution, pharmacokinetics of CNS drug delivery [<xref rid="B30-cancers-16-01594" ref-type="bibr">30</xref>], and endovascular limitations, among others. Here, we discuss these technical considerations, including the role of hemodynamic factors, adjunct imaging techniques, and complication avoidance.</p><p>The pharmacokinetics of IA drug delivery is complex. Critical hydrodynamic factors, including background blood flow, injection parameters, and vascular geometry, wield considerable influence over tissue concentrations subsequent to IA drug injections [<xref rid="B29-cancers-16-01594" ref-type="bibr">29</xref>]. Hence, a fundamental challenge encountered when transitioning IA treatments to clinical settings is the low predictive ability of incomplete pharmacokinetic modeling. Effective IA drug delivery requires rapid and irreversible uptake during first pass circulation, which can be brief, lasting anywhere from 1 to 10 s in the brain [<xref rid="B29-cancers-16-01594" ref-type="bibr">29</xref>,<xref rid="B55-cancers-16-01594" ref-type="bibr">55</xref>]. The prevailing approach hinges on the notion that localized injections capable of transiently elevating arterial drug concentrations will elicit the desired pharmacodynamic effects.</p><p>However, the dearth of rationalized and methodical selection for IA interventions can lead to suboptimal treatment efficacy or failure. Variability in hydrodynamic factors exist across different vascular territories, different tumors, and even within a given tumor, impacting the delivery and efficacy of chemotherapeutics [<xref rid="B56-cancers-16-01594" ref-type="bibr">56</xref>,<xref rid="B57-cancers-16-01594" ref-type="bibr">57</xref>]. For example, the success of IA intervention for retinoblastoma likely hinges on targeting a single tumor type, with a few choices of therapeutic agents delivered to a consistent anatomic territory with a few variations in vascular supply [<xref rid="B24-cancers-16-01594" ref-type="bibr">24</xref>]. Hence, there is a need to understand the key parameters, such as physiologic and anatomic factors impacting regional blood flow, hydrodynamic facets affecting drug distribution, injection parameters, endothelium&#8211;drug interactions, kinetics of BBB uptake and transfer, and site-specific pharmacokinetics [<xref rid="B29-cancers-16-01594" ref-type="bibr">29</xref>]. The high resting blood flow of the brain and its susceptibility to embolic injury are paramount limitations to effective IA drug therapy [<xref rid="B29-cancers-16-01594" ref-type="bibr">29</xref>].</p><p>Advancements in IA drug delivery methods have become pivotal in enhancing therapeutic outcomes. Tumors characterized by low blood flow have demonstrated improved responsiveness to IA chemotherapy [<xref rid="B57-cancers-16-01594" ref-type="bibr">57</xref>]; hence, techniques to transiently reduce or arrest blood flow during therapy administration may be useful [<xref rid="B32-cancers-16-01594" ref-type="bibr">32</xref>,<xref rid="B58-cancers-16-01594" ref-type="bibr">58</xref>]. Approaches include the use of single- or double-balloon catheters designed to isolate proximal and distal arterial flow or anesthetic approaches to decreasing cerebral perfusion. Computational models and preclinical investigations show that, by reducing hydrodynamic stress on injected molecules and extending drug transit time through the cerebral circulation, cerebral hypoperfusion facilitates direct drug delivery to vascular endothelium [<xref rid="B27-cancers-16-01594" ref-type="bibr">27</xref>]. Hyperventilation, hypothermia, or deep anesthesia can induce cerebral hypoperfusion [<xref rid="B29-cancers-16-01594" ref-type="bibr">29</xref>]. Consequently, flow arrest during IA drug administration yields multiple advantages, including enhanced drug targeting to tumor sites, the attainment of higher cerebral arterial concentrations, a more consistent distribution of drug concentrations in arterial networks, and prolonged transit time, with reduced shear stress and the prevention of drug binding to blood proteins or cellular elements [<xref rid="B59-cancers-16-01594" ref-type="bibr">59</xref>].</p><p>The integration of magnetic resonance imaging (MRI) into the guidance of IA infusions may be an advantageous approach, as evidenced by recent preclinical and clinical studies [<xref rid="B60-cancers-16-01594" ref-type="bibr">60</xref>]. Real-time MRI-guided infusion may allow for precise targeting and enhance the assessment of tumor uptake to the intended target area. Pioneering work by Zawadzki et al. demonstrated the technical feasibility and safety of performing targeted IA cerebral infusions under real-time MRI guidance [<xref rid="B61-cancers-16-01594" ref-type="bibr">61</xref>]. This approach is particularly valuable due to the variable vascularity observed in GBM. Real-time MRI guidance during microcatheter may provide crucial quantification of the overlap between the transcatheter perfusion territory and the enhancing mass, enhancing precision and efficacy [<xref rid="B25-cancers-16-01594" ref-type="bibr">25</xref>]. Incorporating cone-beam computed tomography (CBCT) into the planning of IA injections and determining the area of infusion further enhance specificity. CBCT facilitates the generation of perfusion maps, improves the accuracy of IA drug delivery, minimizes the exposure of healthy brain parenchyma, and enhances the therapeutic ratio [<xref rid="B25-cancers-16-01594" ref-type="bibr">25</xref>].</p><p>Complications, including vessel rupture or stroke, although rare, are potentially catastrophic. In some cases, super-selective IA drug delivery may not be technically feasible or may impart an unacceptably high risk to the patient. In the case of tumors supplied by small distal branches that are difficult to access, patients with variant anatomy, or specific technical challenges, the possibility of neurologic complications may be increased, and the precise vascular supply may be difficult to isolate or access. Radiated and recurrent tumors may recruit novel collateral vascular supply, lack discernible angiographic tumor blush, and may be difficult to target endovascularly.</p></sec></sec><sec id="sec3-cancers-16-01594"><title>3. Therapies</title><p>The intra-arterial delivery and SSIACI of multiple chemotherapeutics, radiotherapies, and immunobiological therapies have been studied for the treatment of HGGs (<xref rid="cancers-16-01594-f002" ref-type="fig">Figure 2</xref>). SSIACI may decrease the systemic effects of highly toxic chemotherapeutics or radiotherapies and may increase the local dose that can be delivered to the target tissue. However, many challenges remain. Here, we review specific drugs and targets for the IA drug delivery in the management of HGGs.</p><sec id="sec3dot1-cancers-16-01594"><title>3.1. Chemotherapeutics</title><p>To date, a range of non-selective IA chemotherapeutic agents, including nitrosourea derivatives, platinum analogs, methotrexate, and vincristine, have been employed in the treatment of malignant gliomas [<xref rid="B27-cancers-16-01594" ref-type="bibr">27</xref>]. In addition, various IA chemotherapeutics, such as diaziquone, etoposide, and idarubicin, have also been tested [<xref rid="B21-cancers-16-01594" ref-type="bibr">21</xref>]. Historically, nitrosourea derivatives have been associated with severe neurotoxicity [<xref rid="B16-cancers-16-01594" ref-type="bibr">16</xref>], whereas platinum analogs have demonstrated fewer cerebral side effects [<xref rid="B12-cancers-16-01594" ref-type="bibr">12</xref>]. Temozolomide, a key component of the gold-standard Stupp protocol, has been found to have limited utility in IA infusion [<xref rid="B62-cancers-16-01594" ref-type="bibr">62</xref>], as it requires repetitive cycles to bypass the inherent resistance of glioblastoma stem cells to the drug [<xref rid="B63-cancers-16-01594" ref-type="bibr">63</xref>,<xref rid="B64-cancers-16-01594" ref-type="bibr">64</xref>]. One small phase I study of IA bevacizumab after BBB disruption followed by IV bevacizumab showed a good safety profile with modest but promising results [<xref rid="B64-cancers-16-01594" ref-type="bibr">64</xref>].</p><p>At present, there are several ongoing clinical trials investigating chemotherapy for IA infusion, of which four utilize bevacizumab (<xref rid="cancers-16-01594-t001" ref-type="table">Table 1</xref>). One study is investigating cetuximab, an epidermal growth factor receptor inhibitor found to be well tolerated at high doses [<xref rid="B31-cancers-16-01594" ref-type="bibr">31</xref>]. A phase 0 study testing the blood&#8211;brain barrier (BBB) permeability of temsirolimus, an FDA-approved mTOR inhibitor for renal cell carcinoma, is ongoing. Uluc et al., published a large retrospective analysis of 4939 IA chemotherapy deliveries in 436 patients with various brain tumors (primary central nervous system lymphoma (26.4%), glioblastoma (18.1%), and oligodendroglioma (14.7%)), with and without blood&#8211;brain barrier disruption, using a 25% mannitol infusion, with patients most often receiving a methotrexate injection through the ICA [<xref rid="B65-cancers-16-01594" ref-type="bibr">65</xref>]. They found a higher incidence of seizures in BBB-disruption cases (5.32% vs. 0.18%, <italic toggle="yes">p</italic> &lt; 0.001), but no significant difference was seen in major complications with a rate of &#8804;1% in both groups [<xref rid="B65-cancers-16-01594" ref-type="bibr">65</xref>]. Uluc et al., demonstrated the relative safety and tolerability of IA chemotherapy with enhanced drug delivery to the brain tumor and the surrounding parenchyma [<xref rid="B65-cancers-16-01594" ref-type="bibr">65</xref>]. Lim et al., reported the first rat model of GBM amenable to the testing of bevacizumab, carboplatin, and irinotecan through a left internal carotid artery (ICA) injection [<xref rid="B66-cancers-16-01594" ref-type="bibr">66</xref>]. This model allows for further testing of novel chemotherapeutics and other therapies via endovascular delivery. A recent case series of 12 patients from Chongqing University in China investigated the SSIACI of teniposide, an inhibitor of DNA repair which binds to topoisomerase II [<xref rid="B67-cancers-16-01594" ref-type="bibr">67</xref>], and found encouraging early results [<xref rid="B68-cancers-16-01594" ref-type="bibr">68</xref>]. Endovascular delivery of chemotherapy may have a promising safety profile, but BBB penetration, tumor residence time, and the ideal chemotherapy and its most effective dose are problems that remain to be solved in this space. The SSIACI of bevacizumab has been the most widely studied chemotherapeutic, but ongoing trials of bevacizumab, as well as immunotherapeutics, such as cetuximab, will help to define the future role of SSIACI in the armamentarium of management of HGGs.</p></sec><sec id="sec3dot2-cancers-16-01594"><title>3.2. Radiotherapy</title><p>Targeted radionuclide therapy with &#946;-emitting radionuclides, including Yttrium-90 (Y90) and iodine-131; &#945;-particles; and auger electron emitters have been investigated for their therapeutic efficacy in HGGs [<xref rid="B69-cancers-16-01594" ref-type="bibr">69</xref>]. &#946;-emitting radionuclides have been most extensively studied [<xref rid="B70-cancers-16-01594" ref-type="bibr">70</xref>]; however, &#945;-particles, such as actinium-225, astatine-211, and bismuth-213, may be useful for preventing micro-metastases or treating residual tumors [<xref rid="B69-cancers-16-01594" ref-type="bibr">69</xref>,<xref rid="B71-cancers-16-01594" ref-type="bibr">71</xref>], and auger electron emitters, such as [<sup>125</sup>I]5-Iodo-2&#8242;-deoxyuridine ([<sup>125</sup>I]I-UdR), have been demonstrated to increase therapeutic effects when combined with temozolomide with or without methotrexate [<xref rid="B72-cancers-16-01594" ref-type="bibr">72</xref>]. The IA delivery of Y90 microspheres has been explored as an endovascular brachytherapy treatment for GBM. In a canine model of GBM, a microcatheter technique was employed to selectively infuse Y90 glass microspheres intra-arterially [<xref rid="B73-cancers-16-01594" ref-type="bibr">73</xref>]. At the one-month follow-up after therapy, animals displayed a substantial reduction in mass volume, ranging from 24% to an impressive 94% [<xref rid="B73-cancers-16-01594" ref-type="bibr">73</xref>]. Y90 glass microspheres were FDA approved in the United States for treatment of hepatocellular carcinoma in 2021 [<xref rid="B74-cancers-16-01594" ref-type="bibr">74</xref>], but they are not approved for intracranial use or currently used in clinical settings other than for research. The delivery strategy for radioactive lanthanides, such as Y90, in the context of GBM therapy, involves addressing the formulation of suitable delivery carriers. These carriers should have a high loading capacity for radiotherapeutic agent, be compatible with endovascular techniques and microcatheters, and have the ability to selectively accumulate in the tumor [<xref rid="B75-cancers-16-01594" ref-type="bibr">75</xref>]. One approach is ultrasonic microbubbles with polyvinyl alcohol (PVA) shells to load yttrium into a substrate capable of being delivered by a microcatheter as an endovascular radiopharmaceutical infusion [<xref rid="B76-cancers-16-01594" ref-type="bibr">76</xref>]. Achieving selective targeting of yttrium-loaded microbubbles (MBs) on glioblastoma-associated tumor endothelial cells may be attainable through biorecognition mechanisms. Specifically, the overexpressed &#945;V&#946;3 integrin can interact with the ligand Cyclo(Arg-Gly-Asp-D-Phe-Lys) present on the PVA microbubble surface, facilitating precise delivery to the tumor site [<xref rid="B76-cancers-16-01594" ref-type="bibr">76</xref>]. The main limitation of radiopharmaceuticals includes limited BBB penetration properties of conjugated ligands, heterogeneous antigen expression limiting target-mediated therapy, and translatability from preclinical models [<xref rid="B69-cancers-16-01594" ref-type="bibr">69</xref>]. However, the advantages of IA delivery may help mitigate some of these issues. Future studies on material science, radiotherapeutic loading, BBB penetration, and tumor penetration and targeting are needed to create more effective radiotherapeutic drugs that can be delivered endovascularly.</p></sec><sec id="sec3dot3-cancers-16-01594"><title>3.3. Immunobiologics</title><p>Immunobiologics represents a novel area of cancer therapy and oncology research focused on harnessing and modifying the human immune system to target cancer cells. Within this category, two therapies, oncolytic viruses and chimeric antigen receptor T-cell therapy (CAR-T), have been explored for intra-arterial delivery. Oncolytic viruses (OVs) are a burgeoning area of research in the treatment of GBM [<xref rid="B77-cancers-16-01594" ref-type="bibr">77</xref>]. Briefly, OVs are viruses designed to replicate specifically in tumor cells, inducing oncolysis and developing adaptive immunity [<xref rid="B15-cancers-16-01594" ref-type="bibr">15</xref>,<xref rid="B78-cancers-16-01594" ref-type="bibr">78</xref>]. Adenovirus has been extensively studied for the treatment of GBM, with adenovirus DNX-2401 (formerly known as Delta-24-RGD) used in the first clinical study demonstrating direct oncolysis and providing evidence for a viral-induced anti-glioma immune response [<xref rid="B79-cancers-16-01594" ref-type="bibr">79</xref>,<xref rid="B80-cancers-16-01594" ref-type="bibr">80</xref>]. The use of mesenchymal stem cells (MSCs) for the delivery of DNX-2401 (MSC-DNX-2401) and their ability to target GBMs when delivered IA is now being explored [<xref rid="B15-cancers-16-01594" ref-type="bibr">15</xref>]. DNX-240 has shown success in reducing tumor size and prolonging survival in some GBM patients when administered via intratumoral injections and is currently in a phase I trial for endovascular delivery for recurrent GBM [<xref rid="B80-cancers-16-01594" ref-type="bibr">80</xref>,<xref rid="B81-cancers-16-01594" ref-type="bibr">81</xref>].</p><p>Similarly, CAR-T therapy has demonstrated notable clinical efficacy in diverse solid tumors [<xref rid="B82-cancers-16-01594" ref-type="bibr">82</xref>]. Although the data remain limited regarding CAR-T cell therapy delivery for malignant gliomas, ongoing preclinical and interventional clinical investigations suggest enhanced effectiveness through locoregional delivery. Moreover, researchers have made noteworthy progress in the SSIACI of activated T cells in rabbit models, showcasing safe infusion without catastrophic embolic&#8211;ischemic adverse events [<xref rid="B83-cancers-16-01594" ref-type="bibr">83</xref>].</p><p>Kan et al., developed a rabbit model of GBM that demonstrated the safety of distal ICA delivery of 2 mL of MSC-DNX-2401 in 25 rabbits with histologic evidence of homing to the tumor at 24 h post-injection [<xref rid="B84-cancers-16-01594" ref-type="bibr">84</xref>]. Several new trials of direct intratumoral administration of OVs are ongoing, including a phase II trial of G47-delta an oncolytic herpes virus, adjuvant research combining adenovirus OVs with therapies such as pembrolizumab or CAR-T therapy, and preclinical work in novel OV discovery [<xref rid="B85-cancers-16-01594" ref-type="bibr">85</xref>,<xref rid="B86-cancers-16-01594" ref-type="bibr">86</xref>,<xref rid="B87-cancers-16-01594" ref-type="bibr">87</xref>,<xref rid="B88-cancers-16-01594" ref-type="bibr">88</xref>,<xref rid="B89-cancers-16-01594" ref-type="bibr">89</xref>]. This is of particular relevance, as the development of efficacious intra-arterial delivery of CAR-T cells would represent the frontline of locoregional CAR-T therapy for GBM [<xref rid="B90-cancers-16-01594" ref-type="bibr">90</xref>]. As research continues to progress in immunobiologics therapy for GBM, the novel rabbit GBM model developed by Srinivasan et al., will play a pivotal role in the accelerated bench-to-bedside progression of new therapies.</p></sec><sec id="sec3dot4-cancers-16-01594"><title>3.4. Liquid Embolics</title><p>Traditional pre-operative embolization with liquid embolic agents [<xref rid="B91-cancers-16-01594" ref-type="bibr">91</xref>] has not been typically used in the management of intrinsic HGGs. Some groups have experimented with endoscopic surgery for HGGs with adjuvant pre-operative tumor embolization in order to reduce blood loss and improve the safety of minimally invasive surgery [<xref rid="B92-cancers-16-01594" ref-type="bibr">92</xref>]. Although more commonly utilized in extra-axial brain and head and neck tumors, including meningioma and paraganglioma, arterial embolization may play a role in the multi-modal management of HGGs in select, highly vascular cases with deep arterial supply that may be difficult to access surgically. Future experiments may consider liquid embolics after drug delivery as a potential method to mitigate hemodynamic effects, decrease drug washout, and increase tumor residence time, or as an adjuvant method of decreasing tumoral blood supply.</p></sec></sec><sec id="sec4-cancers-16-01594"><title>4. Future Directions</title><p>Despite the first description of IA drug delivery for HGG in the 1950s [<xref rid="B10-cancers-16-01594" ref-type="bibr">10</xref>,<xref rid="B11-cancers-16-01594" ref-type="bibr">11</xref>], adjunctive endovascular treatments remain experimental. Although super-selective IA cerebral infusions (SSIACIs) offer a tantalizing way to increase the effective drug dose delivered to the target tumor tissue directly with decreased systemic effects, many challenges remain, including the limited ability to penetrate the BBB, challenging pharmacokinetics and hemodynamics, off-target effects, and low drug residence time. Future research targeting these limitations may help bring SSIACI into the future multi-modal treatment regimen for difficult-to-manage HGGs.</p><sec id="sec4dot1-cancers-16-01594"><title>4.1. Endovascular Sampling of Peri-Tumoral Vasculature</title><p>Super-selective catheterization allows for selective sampling from the vessels surrounding a GBM resection cavity. With therapies that modulate the BBB, the ability to obtain highly localized CSF, interstitial fluid, and blood from around the tumor may allow for improved surveillance of recurrence, particularly in patients who have radiation necrosis that mimics recurrence radiographically. Technologies such as liquid tumor biopsy are already being developed and could be paired with endovascular sampling to improve diagnostic yield [<xref rid="B93-cancers-16-01594" ref-type="bibr">93</xref>,<xref rid="B94-cancers-16-01594" ref-type="bibr">94</xref>].</p></sec><sec id="sec4dot2-cancers-16-01594"><title>4.2. Drug Formulations</title><p>Low drug residence times due to high cerebral blood flow and challenging pharmacokinetics remains a limitation of IA drug delivery. Nanoparticle-encapsulated talazoparib injected intrathecally has shown promise for increasing penetration and therapeutic index [<xref rid="B95-cancers-16-01594" ref-type="bibr">95</xref>]. Similar encapsulated drug formulations may be translated to endovascular interventions to improve tumor targeting and increasing treatment efficacy. Rainov et al., used a herpes simplex virus vector and monocrystalline iron oxide nanoparticles in conjunction with bradykinin-mediated blood&#8211;tumor barrier disruption to target gliosarcomas in rats and demonstrated improved uptake and viral-mediated gene delivery [<xref rid="B96-cancers-16-01594" ref-type="bibr">96</xref>]. Ligand conjugation is a strategy that actively targets endothelial cell receptors such as transferrin receptors, insulin receptors, or lipoprotein receptors that may improve the ability to cross the BBB and target specific brain regions [<xref rid="B97-cancers-16-01594" ref-type="bibr">97</xref>,<xref rid="B98-cancers-16-01594" ref-type="bibr">98</xref>]. Additionally, several novel nanoparticle systems for the delivery of drugs to brain tumors have been developed but have not been trialed in IA delivery systems [<xref rid="B99-cancers-16-01594" ref-type="bibr">99</xref>]. Together with improved endovascular delivery techniques, these new nanoparticle formulations may improve brain-tumor treatments moving forward. Applications of advances in materials science, nanoparticles, and novel drug formulations that improve BBB crossing and/or increase drug&#8211;tumor residence time may improve the efficacy of super-selective IA drug delivery in the future [<xref rid="B100-cancers-16-01594" ref-type="bibr">100</xref>,<xref rid="B101-cancers-16-01594" ref-type="bibr">101</xref>].</p></sec><sec id="sec4dot3-cancers-16-01594"><title>4.3. Endovascular Delivery of Non-Pharmaceutical Therapies</title><p>One unique advantage of endovascular drug delivery is the option to go beyond medication delivery and offer endovascular embolization as well. Targeted radioembolization may be a potential pre-operative adjuvant therapy to help reduce microscopic seeding and decrease local recurrence [<xref rid="B76-cancers-16-01594" ref-type="bibr">76</xref>]. Intra-operative photodynamic exposure to a tumor premedicated with 5-ALA may induce a thermally mediated and immunologically mediate tumor ablation [<xref rid="B102-cancers-16-01594" ref-type="bibr">102</xref>,<xref rid="B103-cancers-16-01594" ref-type="bibr">103</xref>]. Endovascular catheters could potentially provide a light source for minimally invasive, highly selective delivery to the tumor. Further research into photodynamic endovascular therapy could provide promise for localized GBM ablation.</p></sec></sec><sec sec-type="conclusions" id="sec5-cancers-16-01594"><title>5. Conclusions</title><p>The potential benefits of endovascular intervention for GBM treatment are plentiful, underscored most prominently with the promise of flexible, multimodal, and targeted chemotherapeutic delivery while minimizing systemic toxicity. Several studies have proven the safety of SSIACI in its ability to deliver chemotherapeutics. Promising phase I and phase II studies have demonstrated moderate efficacy. Nonetheless, large, randomized phase III trials have been limited by high costs and patient-recruitment challenges and limit the interpretation of SSIACI efficacy. Nevertheless, with a better understanding of GBM morphology, improved chemotherapeutics, BBB disruption formulations, and refinement of clinical techniques, endovascular approaches hold high promise for improving patient outcomes while minimizing chemotoxicity.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.D.K., M.A.A.-S. and J.D.B.; supervision A.D.K., M.A.A.-S. and J.D.B.; writing&#8212;original draft, R.J., A.D.K., S.G., W.J.S. and J.D.B.; writing&#8212;review and editing, A.D.K., R.J., S.G., W.J.S., A.H.F., A.A.D., J.V.-P., R.E.A.G., F.A.G., N.J.P., R.D., A.P.S., P.P.P., M.A.A.-S. and J.D.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>J.D.B. has an equity position in Treovir Inc. and UpFront Diagnostics. J.D.B. is also on the Centile Bioscience, QV Bioelectronics and NeuroX1 boards of scientific advisors.</p></notes><ref-list><title>References</title><ref id="B1-cancers-16-01594"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Kesari</surname><given-names>S.</given-names></name></person-group><article-title>Malignant gliomas in adults</article-title><source>N. Engl. J. Med.</source><year>2008</year><volume>359</volume><fpage>492</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0708126</pub-id><pub-id pub-id-type="pmid">18669428</pub-id></element-citation></ref><ref id="B2-cancers-16-01594"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostrom</surname><given-names>Q.T.</given-names></name><name name-style="western"><surname>Gittleman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rouse</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wolinsky</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kruchko</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barnholtz-Sloan</surname><given-names>J.</given-names></name></person-group><article-title>CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007&#8211;2011</article-title><source>Neuro Oncol.</source><year>2014</year><volume>16</volume><issue>(Suppl. S4)</issue><fpage>iv1</fpage><lpage>iv63</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nou223</pub-id><pub-id pub-id-type="pmid">25304271</pub-id><pub-id pub-id-type="pmcid">PMC4193675</pub-id></element-citation></ref><ref id="B3-cancers-16-01594"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Weller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.Q.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Barnholtz-Sloan</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Barthel</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Batchelor</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Bindra</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Chiocca</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions</article-title><source>Neuro Oncol.</source><year>2020</year><volume>22</volume><fpage>1073</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noaa106</pub-id><pub-id pub-id-type="pmid">32328653</pub-id><pub-id pub-id-type="pmcid">PMC7594557</pub-id></element-citation></ref><ref id="B4-cancers-16-01594"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marenco-Hillembrand</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wijesekera</surname><given-names>O.</given-names></name><name name-style="western"><surname>Suarez-Meade</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mampre</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Trifiletti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hammack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lesser</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Trends in glioblastoma: Outcomes over time and type of intervention: A systematic evidence based analysis</article-title><source>J. Neuro-Oncol.</source><year>2020</year><volume>147</volume><fpage>297</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1007/s11060-020-03451-6</pub-id><pub-id pub-id-type="pmid">32157552</pub-id></element-citation></ref><ref id="B5-cancers-16-01594"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bikfalvi</surname><given-names>A.</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Avril</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barnier</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Bauchet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brisson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cartron</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Castel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chevet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chneiweiss</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Challenges in glioblastoma research: Focus on the tumor microenvironment</article-title><source>Trends Cancer</source><year>2023</year><volume>9</volume><fpage>9</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2022.09.005</pub-id><pub-id pub-id-type="pmid">36400694</pub-id></element-citation></ref><ref id="B6-cancers-16-01594"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rapp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baernreuther</surname><given-names>J.</given-names></name><name name-style="western"><surname>Turowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Steiger</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Sabel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamp</surname><given-names>M.A.</given-names></name></person-group><article-title>Recurrence Pattern Analysis of Primary Glioblastoma</article-title><source>World Neurosurg.</source><year>2017</year><volume>103</volume><fpage>733</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2017.04.053</pub-id><pub-id pub-id-type="pmid">28434963</pub-id></element-citation></ref><ref id="B7-cancers-16-01594"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandes</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Tosoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Frezza</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amist&#224;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morandi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spagnolli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ermani</surname><given-names>M.</given-names></name></person-group><article-title>Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation With MGMT promoter methylation status</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>27</volume><fpage>1275</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.19.4969</pub-id><pub-id pub-id-type="pmid">19188675</pub-id></element-citation></ref><ref id="B8-cancers-16-01594"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broekman</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Maas</surname><given-names>S.L.N.</given-names></name><name name-style="western"><surname>Abels</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Mempel</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Krichevsky</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Breakefield</surname><given-names>X.O.</given-names></name></person-group><article-title>Multidimensional communication in the microenvirons of glioblastoma</article-title><source>Nat. Rev. Neurol.</source><year>2018</year><volume>14</volume><fpage>482</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0025-8</pub-id><pub-id pub-id-type="pmid">29985475</pub-id><pub-id pub-id-type="pmcid">PMC6425928</pub-id></element-citation></ref><ref id="B9-cancers-16-01594"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Solinge</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Nieland</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chiocca</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Broekman</surname><given-names>M.L.D.</given-names></name></person-group><article-title>Advances in local therapy for glioblastoma&#8212;Taking the fight to the tumour</article-title><source>Nat. Rev. Neurol.</source><year>2022</year><volume>18</volume><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/s41582-022-00621-0</pub-id><pub-id pub-id-type="pmid">35277681</pub-id><pub-id pub-id-type="pmcid">PMC10359969</pub-id></element-citation></ref><ref id="B10-cancers-16-01594"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klopp</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Alford</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Winship</surname><given-names>T.</given-names></name></person-group><article-title>Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report</article-title><source>Ann. Surg.</source><year>1950</year><volume>132</volume><fpage>811</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1097/00000658-195010000-00018</pub-id><pub-id pub-id-type="pmid">14771793</pub-id><pub-id pub-id-type="pmcid">PMC1616816</pub-id></element-citation></ref><ref id="B11-cancers-16-01594"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>French</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>West</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Von Amerongen</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Magoun</surname><given-names>H.W.</given-names></name></person-group><article-title>Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors</article-title><source>J. Neurosurg.</source><year>1952</year><volume>9</volume><fpage>378</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.3171/jns.1952.9.4.0378</pub-id><pub-id pub-id-type="pmid">14946578</pub-id></element-citation></ref><ref id="B12-cancers-16-01594"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peschillo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miscusi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Missori</surname><given-names>P.</given-names></name></person-group><article-title>Endovascular superselective treatment of brain tumors: A new endovascular era? A quick review</article-title><source>J. Neurointerv. Surg.</source><year>2015</year><volume>7</volume><fpage>222</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1136/neurintsurg-2013-011095</pub-id><pub-id pub-id-type="pmid">24510377</pub-id></element-citation></ref><ref id="B13-cancers-16-01594"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imbesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marchioni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Benericetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zappoli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ceroni</surname><given-names>M.</given-names></name></person-group><article-title>A randomized phase III study: Comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas</article-title><source>Anticancer. Res.</source><year>2006</year><volume>26</volume><fpage>553</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">16739319</pub-id></element-citation></ref><ref id="B14-cancers-16-01594"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>R.</given-names></name><name name-style="western"><surname>Feroze</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lawton</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Choudhri</surname><given-names>O.</given-names></name></person-group><article-title>Endovascular therapies for malignant gliomas: Challenges and the future</article-title><source>J. Clin. Neurosci.</source><year>2016</year><volume>26</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2015.10.019</pub-id><pub-id pub-id-type="pmid">26857294</pub-id></element-citation></ref><ref id="B15-cancers-16-01594"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>P.</given-names></name></person-group><article-title>Intraarterial delivery of virotherapy for glioblastoma</article-title><source>Neurosurg. Focus.</source><year>2021</year><volume>50</volume><fpage>E7</fpage><pub-id pub-id-type="doi">10.3171/2020.11.FOCUS20845</pub-id><pub-id pub-id-type="pmid">33524944</pub-id></element-citation></ref><ref id="B16-cancers-16-01594"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shapiro</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Green</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Selker</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>VanGilder</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Mealey</surname><given-names>J.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Ransohff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahaley</surname><given-names>M.S.</given-names><suffix>Jr.</suffix></name></person-group><article-title>A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma</article-title><source>J. Neurosurg.</source><year>1992</year><volume>76</volume><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.3171/jns.1992.76.5.0772</pub-id><pub-id pub-id-type="pmid">1564540</pub-id></element-citation></ref><ref id="B17-cancers-16-01594"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuur</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Simis</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lansdaal</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Schornagel</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Dreschler</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Rasch</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Balm</surname><given-names>A.J.</given-names></name></person-group><article-title>Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer</article-title><source>J. Clin. Oncol.</source><year>2007</year><volume>25</volume><fpage>3759</fpage><lpage>3765</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.08.9540</pub-id><pub-id pub-id-type="pmid">17704425</pub-id></element-citation></ref><ref id="B18-cancers-16-01594"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peschillo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caporlingua</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diana</surname><given-names>F.</given-names></name><name name-style="western"><surname>Caporlingua</surname><given-names>F.</given-names></name><name name-style="western"><surname>Delfini</surname><given-names>R.</given-names></name></person-group><article-title>New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it</article-title><source>J. Neurointerv. Surg.</source><year>2016</year><volume>8</volume><fpage>1078</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1136/neurintsurg-2015-012048</pub-id><pub-id pub-id-type="pmid">26541791</pub-id></element-citation></ref><ref id="B19-cancers-16-01594"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gogna</surname><given-names>A.</given-names></name></person-group><article-title>Use of the triple coaxial (triaxial) microcatheter system in superselective arterial embolisation for complex interventional cases: An initial experience with the system</article-title><source>CVIR Endovasc.</source><year>2022</year><volume>5</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/s42155-022-00340-z</pub-id><pub-id pub-id-type="pmid">36562878</pub-id><pub-id pub-id-type="pmcid">PMC9789256</pub-id></element-citation></ref><ref id="B20-cancers-16-01594"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Northcutt</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sheu</surname><given-names>Y.R.</given-names></name><name name-style="western"><surname>Carmi</surname><given-names>L.</given-names></name></person-group><article-title>Wires, Catheters, and More: A Primer for Residents and Fellows Entering Interventional Radiology: Resident and Fellow Education Feature</article-title><source>Radiographics</source><year>2015</year><volume>35</volume><fpage>1621</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.1148/rg.2015130155</pub-id><pub-id pub-id-type="pmid">26371584</pub-id></element-citation></ref><ref id="B21-cancers-16-01594"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinkiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pinkiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walecki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zawadzki</surname><given-names>M.</given-names></name></person-group><article-title>A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><fpage>950167</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.950167</pub-id><pub-id pub-id-type="pmid">36212394</pub-id><pub-id pub-id-type="pmcid">PMC9539841</pub-id></element-citation></ref><ref id="B22-cancers-16-01594"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Amico</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Khatri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reichman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fralin</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: Where are we now, and where we are going</article-title><source>J. Neuro-Oncol.</source><year>2020</year><volume>147</volume><fpage>261</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1007/s11060-020-03435-6</pub-id><pub-id pub-id-type="pmid">32076934</pub-id></element-citation></ref><ref id="B23-cancers-16-01594"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Froehler</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nunnally</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Calcutt</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Bridges</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>LaNeve</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Reyzer</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2018</year><volume>59</volume><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1167/iovs.17-22302</pub-id><pub-id pub-id-type="pmid">29368001</pub-id><pub-id pub-id-type="pmcid">PMC5783625</pub-id></element-citation></ref><ref id="B24-cancers-16-01594"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Froehler</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Kaczmarek</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Bogan</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Santapuram</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Schremp</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.K.</given-names></name><etal/></person-group><article-title>Efficacy, Toxicity, and Pharmacokinetics of Intra-Arterial Chemotherapy Versus Intravenous Chemotherapy for Retinoblastoma in Animal Models and Patients</article-title><source>Transl. Vis. Sci. Technol.</source><year>2021</year><volume>10</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1167/tvst.10.11.10</pub-id><pub-id pub-id-type="pmid">34495330</pub-id><pub-id pub-id-type="pmcid">PMC8431978</pub-id></element-citation></ref><ref id="B25-cancers-16-01594"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ene</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>P.</given-names></name></person-group><article-title>Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors</article-title><source>J. Neurointerv. Surg.</source><year>2022</year><volume>14</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1136/neurintsurg-2021-018190</pub-id><pub-id pub-id-type="pmid">34824133</pub-id></element-citation></ref><ref id="B26-cancers-16-01594"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobin</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Cloughesy</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Duckwiler</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Sayre</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Milanese</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vi&#241;uela</surname><given-names>F.</given-names></name></person-group><article-title>Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery</article-title><source>Radiology</source><year>2001</year><volume>218</volume><fpage>724</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1148/radiology.218.3.r01mr41724</pub-id><pub-id pub-id-type="pmid">11230646</pub-id></element-citation></ref><ref id="B27-cancers-16-01594"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkhardt</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Riina</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Moliterno</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Boockvar</surname><given-names>J.A.</given-names></name></person-group><article-title>Intra-arterial chemotherapy for malignant gliomas: A critical analysis</article-title><source>Interv. Neuroradiol.</source><year>2011</year><volume>17</volume><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1177/159101991101700302</pub-id><pub-id pub-id-type="pmid">22005689</pub-id><pub-id pub-id-type="pmcid">PMC3396041</pub-id></element-citation></ref><ref id="B28-cancers-16-01594"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saris</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Blasberg</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>deVroom</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dedrick</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Pettigrew</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Doppman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration</article-title><source>J. Neurosurg.</source><year>1991</year><volume>74</volume><fpage>763</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.3171/jns.1991.74.5.0763</pub-id><pub-id pub-id-type="pmid">1849555</pub-id></element-citation></ref><ref id="B29-cancers-16-01594"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Banu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Singh-Moon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lavine</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>S.</given-names></name></person-group><article-title>Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme Treatment</article-title><source>J. Drug Deliv.</source><year>2015</year><volume>2015</volume><fpage>405735</fpage><pub-id pub-id-type="doi">10.1155/2015/405735</pub-id><pub-id pub-id-type="pmid">26819758</pub-id><pub-id pub-id-type="pmcid">PMC4706947</pub-id></element-citation></ref><ref id="B30-cancers-16-01594"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fortin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morin</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Belzile</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Par&#233;</surname><given-names>F.M.</given-names></name></person-group><article-title>Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme</article-title><source>J. Neuro-Oncol.</source><year>2014</year><volume>119</volume><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1007/s11060-014-1504-4</pub-id><pub-id pub-id-type="pmid">24947313</pub-id></element-citation></ref><ref id="B31-cancers-16-01594"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Filippi</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fralin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsiouris</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Praminick</surname><given-names>B.</given-names></name><name name-style="western"><surname>Demopoulos</surname><given-names>A.</given-names></name><name name-style="western"><surname>McCrea</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Bodhinayake</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: Phase I study</article-title><source>J. Neuro-Oncol.</source><year>2016</year><volume>128</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1007/s11060-016-2099-8</pub-id><pub-id pub-id-type="pmid">26945581</pub-id></element-citation></ref><ref id="B32-cancers-16-01594"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh-Moon</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reif</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Bigio</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Straubinger</surname><given-names>R.M.</given-names></name></person-group><article-title>Cerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing rats</article-title><source>Neurosurgery</source><year>2015</year><volume>76</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1227/NEU.0000000000000552</pub-id><pub-id pub-id-type="pmid">25525695</pub-id><pub-id pub-id-type="pmcid">PMC4273869</pub-id></element-citation></ref><ref id="B33-cancers-16-01594"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haumann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Videira</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Kaspers</surname><given-names>G.J.L.</given-names></name><name name-style="western"><surname>van Vuurden</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Hulleman</surname><given-names>E.</given-names></name></person-group><article-title>Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors</article-title><source>CNS Drugs</source><year>2020</year><volume>34</volume><fpage>1121</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1007/s40263-020-00766-w</pub-id><pub-id pub-id-type="pmid">32965590</pub-id><pub-id pub-id-type="pmcid">PMC7658069</pub-id></element-citation></ref><ref id="B34-cancers-16-01594"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuwelt</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Maravilla</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Frenkel</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Rapaport</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>P.A.</given-names></name></person-group><article-title>Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery</article-title><source>J. Clin. Investig.</source><year>1979</year><volume>64</volume><fpage>684</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1172/JCI109509</pub-id><pub-id pub-id-type="pmid">457877</pub-id><pub-id pub-id-type="pmcid">PMC372166</pub-id></element-citation></ref><ref id="B35-cancers-16-01594"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angeli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Janin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bousquet</surname><given-names>G.</given-names></name></person-group><article-title>How to Make Anticancer Drugs Cross the Blood-Brain Barrier to Treat Brain Metastases</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>21</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21010022</pub-id><pub-id pub-id-type="pmid">31861465</pub-id><pub-id pub-id-type="pmcid">PMC6981899</pub-id></element-citation></ref><ref id="B36-cancers-16-01594"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostermann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Leyvraz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lejeune</surname><given-names>F.</given-names></name><name name-style="western"><surname>Decosterd</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Stupp</surname><given-names>R.</given-names></name></person-group><article-title>Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients</article-title><source>Clin. Cancer Res.</source><year>2004</year><volume>10</volume><fpage>3728</fpage><lpage>3736</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0807</pub-id><pub-id pub-id-type="pmid">15173079</pub-id></element-citation></ref><ref id="B37-cancers-16-01594"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaney</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Balis</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Godwin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Poplack</surname><given-names>D.G.</given-names></name></person-group><article-title>Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates</article-title><source>Cancer Res.</source><year>1993</year><volume>53</volume><fpage>725</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">8428353</pub-id></element-citation></ref><ref id="B38-cancers-16-01594"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>McCully</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Montuenga</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Balis</surname><given-names>F.M.</given-names></name></person-group><article-title>Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates</article-title><source>Cancer Chemother. Pharmacol.</source><year>2000</year><volume>45</volume><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1007/s002800050031</pub-id><pub-id pub-id-type="pmid">10663638</pub-id></element-citation></ref><ref id="B39-cancers-16-01594"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>S.</given-names></name><name name-style="western"><surname>McCully</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Bacher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Balis</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>E.</given-names></name></person-group><article-title>Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates</article-title><source>Cancer Chemother. Pharmacol.</source><year>2010</year><volume>65</volume><fpage>817</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1007/s00280-009-1085-7</pub-id><pub-id pub-id-type="pmid">19662415</pub-id><pub-id pub-id-type="pmcid">PMC6936607</pub-id></element-citation></ref><ref id="B40-cancers-16-01594"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Csordas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hegyi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eipel</surname><given-names>O.T.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Erdelyi</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.T.</given-names></name></person-group><article-title>Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia</article-title><source>Anticancer. Drugs</source><year>2013</year><volume>24</volume><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1097/CAD.0b013e32835b8662</pub-id><pub-id pub-id-type="pmid">23187460</pub-id></element-citation></ref><ref id="B41-cancers-16-01594"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kellie</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Barbaric</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>P.</given-names></name><name name-style="western"><surname>Earl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>de Graaf</surname><given-names>S.S.</given-names></name></person-group><article-title>Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: A surrogate marker of brain penetration</article-title><source>Cancer</source><year>2002</year><volume>94</volume><fpage>1815</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1002/cncr.10397</pub-id><pub-id pub-id-type="pmid">11920545</pub-id></element-citation></ref><ref id="B42-cancers-16-01594"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zylber-Katz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gomori</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lossos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bokstein</surname><given-names>F.</given-names></name><name name-style="western"><surname>Siegal</surname><given-names>T.</given-names></name></person-group><article-title>Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma</article-title><source>Clin. Pharmacol. Ther.</source><year>2000</year><volume>67</volume><fpage>631</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.106932</pub-id><pub-id pub-id-type="pmid">10872645</pub-id></element-citation></ref><ref id="B43-cancers-16-01594"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellavance</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Blanchette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>D.</given-names></name></person-group><article-title>Recent advances in blood-brain barrier disruption as a CNS delivery strategy</article-title><source>AAPS J.</source><year>2008</year><volume>10</volume><fpage>166</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1208/s12248-008-9018-7</pub-id><pub-id pub-id-type="pmid">18446517</pub-id><pub-id pub-id-type="pmcid">PMC2751463</pub-id></element-citation></ref><ref id="B44-cancers-16-01594"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasgupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kiessling</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lammers</surname><given-names>T.</given-names></name></person-group><article-title>Ultrasound-mediated drug delivery to the brain: Principles, progress and prospects</article-title><source>Drug Discov. Today Technol.</source><year>2016</year><volume>20</volume><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2016.07.007</pub-id><pub-id pub-id-type="pmid">27986222</pub-id><pub-id pub-id-type="pmcid">PMC5166975</pub-id></element-citation></ref><ref id="B45-cancers-16-01594"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hough</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hynynen</surname><given-names>K.</given-names></name></person-group><article-title>Focused ultrasound-mediated drug delivery through the blood-brain barrier</article-title><source>Expert. Rev. Neurother.</source><year>2015</year><volume>15</volume><fpage>477</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1586/14737175.2015.1028369</pub-id><pub-id pub-id-type="pmid">25936845</pub-id><pub-id pub-id-type="pmcid">PMC4702264</pub-id></element-citation></ref><ref id="B46-cancers-16-01594"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>N.</given-names></name><name name-style="western"><surname>Taniyama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Endoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurinami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ogihara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaneda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>R.</given-names></name></person-group><article-title>Development of efficient plasmid DNA transfer into adult rat central nervous system using microbubble-enhanced ultrasound</article-title><source>Gene Ther.</source><year>2004</year><volume>11</volume><fpage>1532</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302323</pub-id><pub-id pub-id-type="pmid">15269716</pub-id></element-citation></ref><ref id="B47-cancers-16-01594"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>K.C.</given-names></name></person-group><article-title>Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: An overview of the current preclinical status</article-title><source>Neurosurg. Focus.</source><year>2012</year><volume>32</volume><fpage>E4</fpage><pub-id pub-id-type="doi">10.3171/2011.10.FOCUS11238</pub-id><pub-id pub-id-type="pmid">22208897</pub-id></element-citation></ref><ref id="B48-cancers-16-01594"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salgaonkar</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Diederich</surname><given-names>C.J.</given-names></name></person-group><article-title>Catheter-based ultrasound technology for image-guided thermal therapy: Current technology and applications</article-title><source>Int. J. Hyperthermia</source><year>2015</year><volume>31</volume><fpage>203</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.3109/02656736.2015.1006269</pub-id><pub-id pub-id-type="pmid">25799287</pub-id><pub-id pub-id-type="pmcid">PMC4659534</pub-id></element-citation></ref><ref id="B49-cancers-16-01594"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghoshal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gee</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heffter</surname><given-names>T.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bromfield</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rund</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ehrhardt</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Diederich</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Pilitsis</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>A minimally invasive catheter-based ultrasound technology for therapeutic interventions in brain: Initial preclinical studies</article-title><source>Neurosurg. Focus.</source><year>2018</year><volume>44</volume><fpage>E13</fpage><pub-id pub-id-type="doi">10.3171/2017.11.FOCUS17631</pub-id><pub-id pub-id-type="pmcid">PMC5891098</pub-id><pub-id pub-id-type="pmid">29385920</pub-id></element-citation></ref><ref id="B50-cancers-16-01594"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Power</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Rechberger</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Nesvick</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hinchcliffe</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Elmquist</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>D.J.</given-names></name></person-group><article-title>Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time</article-title><source>Neurooncol. Adv.</source><year>2023</year><volume>5</volume><fpage>vdad033</fpage><pub-id pub-id-type="doi">10.1093/noajnl/vdad033</pub-id><pub-id pub-id-type="pmid">37128506</pub-id><pub-id pub-id-type="pmcid">PMC10148679</pub-id></element-citation></ref><ref id="B51-cancers-16-01594"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copeland</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Pompliano</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Meek</surname><given-names>T.D.</given-names></name></person-group><article-title>Drug-target residence time and its implications for lead optimization</article-title><source>Nat. Rev. Drug Discov.</source><year>2006</year><volume>5</volume><fpage>730</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/nrd2082</pub-id><pub-id pub-id-type="pmid">16888652</pub-id></element-citation></ref><ref id="B52-cancers-16-01594"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copeland</surname><given-names>R.A.</given-names></name></person-group><article-title>The drug-target residence time model: A 10-year retrospective</article-title><source>Nat. Rev. Drug Discov.</source><year>2016</year><volume>15</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/nrd.2015.18</pub-id><pub-id pub-id-type="pmid">26678621</pub-id></element-citation></ref><ref id="B53-cancers-16-01594"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dismuke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Malawsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Godfrey</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Kabanov</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Gershon</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Sokolsky-Papkov</surname><given-names>M.</given-names></name></person-group><article-title>Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib</article-title><source>Sci. Adv.</source><year>2022</year><volume>8</volume><fpage>eabl5838</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abl5838</pub-id><pub-id pub-id-type="pmid">35080986</pub-id><pub-id pub-id-type="pmcid">PMC8791615</pub-id></element-citation></ref><ref id="B54-cancers-16-01594"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.S.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kodani</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morisseau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hammock</surname><given-names>B.D.</given-names></name></person-group><article-title>Drug-Target Residence Time Affects in Vivo Target Occupancy through Multiple Pathways</article-title><source>ACS Cent. Sci.</source><year>2019</year><volume>5</volume><fpage>1614</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.9b00770</pub-id><pub-id pub-id-type="pmid">31572788</pub-id><pub-id pub-id-type="pmcid">PMC6764161</pub-id></element-citation></ref><ref id="B55-cancers-16-01594"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cenic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nabavi</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Craen</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Gelb</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.Y.</given-names></name></person-group><article-title>Dynamic CT measurement of cerebral blood flow: A validation study</article-title><source>AJNR Am. J. Neuroradiol.</source><year>1999</year><volume>20</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">9974059</pub-id></element-citation></ref><ref id="B56-cancers-16-01594"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Platzek</surname><given-names>I.</given-names></name><name name-style="western"><surname>Seidlitz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mutsaerts</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Hofheinz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schramm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beuthien-Baumann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>M.</given-names></name><name name-style="western"><surname>van den Hoff</surname><given-names>J.</given-names></name></person-group><article-title>Early and late effects of radiochemotherapy on cerebral blood flow in glioblastoma patients measured with non-invasive perfusion MRI</article-title><source>Radiother. Oncol.</source><year>2016</year><volume>118</volume><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2015.12.017</pub-id><pub-id pub-id-type="pmid">26747756</pub-id></element-citation></ref><ref id="B57-cancers-16-01594"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Gobin</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Cloughesy</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sayre</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Villablanca</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Vi&#241;uela</surname><given-names>F.</given-names></name></person-group><article-title>Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy</article-title><source>AJNR Am. J. Neuroradiol.</source><year>2000</year><volume>21</volume><fpage>471</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">10730637</pub-id><pub-id pub-id-type="pmcid">PMC8174969</pub-id></element-citation></ref><ref id="B58-cancers-16-01594"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riina</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Greenfield</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Fralin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gobin</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Tsiouris</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Souweidane</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Boockvar</surname><given-names>J.A.</given-names></name></person-group><article-title>Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note</article-title><source>Interv. Neuroradiol.</source><year>2010</year><volume>16</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1177/159101991001600109</pub-id><pub-id pub-id-type="pmid">20377982</pub-id><pub-id pub-id-type="pmcid">PMC3277958</pub-id></element-citation></ref><ref id="B59-cancers-16-01594"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Etu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Suckow</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Feinmark</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Fine</surname><given-names>R.L.</given-names></name></person-group><article-title>Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue</article-title><source>J. Neuro-Oncol.</source><year>2008</year><volume>86</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/s11060-007-9450-z</pub-id><pub-id pub-id-type="pmid">17634743</pub-id></element-citation></ref><ref id="B60-cancers-16-01594"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walczak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pearl</surname><given-names>M.S.</given-names></name></person-group><article-title>Predicting and optimizing the territory of blood-brain barrier opening by superselective intra-arterial cerebral infusion under dynamic susceptibility contrast MRI guidance</article-title><source>J. Cereb. Blood Flow. Metab.</source><year>2016</year><volume>36</volume><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1177/0271678X15615875</pub-id><pub-id pub-id-type="pmid">26661231</pub-id><pub-id pub-id-type="pmcid">PMC4794102</pub-id></element-citation></ref><ref id="B61-cancers-16-01594"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zawadzki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walecki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kostkiewicz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kostyra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pearl</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Solaiyappan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walczak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Janowski</surname><given-names>M.</given-names></name></person-group><article-title>Real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: Technical note</article-title><source>BMJ Case Rep.</source><year>2019</year><volume>12</volume><fpage>bcr-2018</fpage><pub-id pub-id-type="doi">10.1136/bcr-2018-014469</pub-id><pub-id pub-id-type="pmid">30679227</pub-id><pub-id pub-id-type="pmcid">PMC6347944</pub-id></element-citation></ref><ref id="B62-cancers-16-01594"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muldoon</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Pagel</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Netto</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Neuwelt</surname><given-names>E.A.</given-names></name></person-group><article-title>Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity</article-title><source>J. Neuro-Oncol.</source><year>2016</year><volume>126</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1007/s11060-015-2000-1</pub-id><pub-id pub-id-type="pmid">26694547</pub-id></element-citation></ref><ref id="B63-cancers-16-01594"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Codrici</surname><given-names>E.</given-names></name><name name-style="western"><surname>Enciu</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Popescu</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Mihai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanase</surname><given-names>C.</given-names></name></person-group><article-title>Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets</article-title><source>Stem Cells Int.</source><year>2016</year><volume>2016</volume><fpage>5728438</fpage><pub-id pub-id-type="doi">10.1155/2016/5728438</pub-id><pub-id pub-id-type="pmid">26977157</pub-id><pub-id pub-id-type="pmcid">PMC4764748</pub-id></element-citation></ref><ref id="B64-cancers-16-01594"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkhardt</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Riina</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Christos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kesavabhotla</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Tsiouris</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Boockvar</surname><given-names>J.A.</given-names></name></person-group><article-title>Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: Progression-free survival and overall survival</article-title><source>World Neurosurg.</source><year>2012</year><volume>77</volume><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2011.05.056</pub-id><pub-id pub-id-type="pmid">22405392</pub-id><pub-id pub-id-type="pmcid">PMC3743246</pub-id></element-citation></ref><ref id="B65-cancers-16-01594"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uluc</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ambady</surname><given-names>P.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Tabb</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Kersch</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Nerison</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Huddleston</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Dogan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Priest</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Safety of intra-arterial chemotherapy with or without osmotic blood-brain barrier disruption for the treatment of patients with brain tumors</article-title><source>Neurooncol Adv.</source><year>2022</year><volume>4</volume><fpage>vdac104</fpage><pub-id pub-id-type="doi">10.1093/noajnl/vdac104</pub-id><pub-id pub-id-type="pmid">35892048</pub-id><pub-id pub-id-type="pmcid">PMC9307096</pub-id></element-citation></ref><ref id="B66-cancers-16-01594"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baig</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Pol</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Koenigsknecht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pionessa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tutino</surname><given-names>V.M.</given-names></name><etal/></person-group><article-title>The first endovascular rat glioma model for pre-clinical evaluation of intra-arterial therapeutics</article-title><source>Interv. Neuroradiol.</source><year>2024</year><fpage>15910199231169597</fpage><pub-id pub-id-type="doi">10.1227/neu.0000000000002809_388</pub-id><pub-id pub-id-type="pmid">37157800</pub-id></element-citation></ref><ref id="B67-cancers-16-01594"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>E.</given-names></name></person-group><article-title>Recent Advances in the Application of Podophyllotoxin Derivatives to Fight Against Multidrug-Resistant Cancer Cells</article-title><source>Curr. Top. Med. Chem.</source><year>2021</year><volume>21</volume><fpage>1712</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.2174/1568026621666210113163327</pub-id><pub-id pub-id-type="pmid">33441065</pub-id></element-citation></ref><ref id="B68-cancers-16-01594"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Safety and feasibility of intra-arterial delivery of teniposide to high grade gliomas after blood-brain barrier disruption: A case series</article-title><source>J. Neurointerv. Surg.</source><year>2023</year><pub-id pub-id-type="doi">10.1136/jnis-2023-021055</pub-id><pub-id pub-id-type="pmid">38071559</pub-id><pub-id pub-id-type="pmcid">PMC11503114</pub-id></element-citation></ref><ref id="B69-cancers-16-01594"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolcaen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kleynhans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verhoeven</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goethals</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sathekge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vandevoorde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ebenhan</surname><given-names>T.</given-names></name></person-group><article-title>A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>7911</fpage><lpage>7947</lpage><pub-id pub-id-type="doi">10.7150/thno.56639</pub-id><pub-id pub-id-type="pmid">34335972</pub-id><pub-id pub-id-type="pmcid">PMC8315062</pub-id></element-citation></ref><ref id="B70-cancers-16-01594"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gudkov</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Shilyagina</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Vodeneev</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Zvyagin</surname><given-names>A.V.</given-names></name></person-group><article-title>Targeted Radionuclide Therapy of Human Tumors</article-title><source>Int. J. Mol. Sci.</source><year>2015</year><volume>17</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17010033</pub-id><pub-id pub-id-type="pmid">26729091</pub-id><pub-id pub-id-type="pmcid">PMC4730279</pub-id></element-citation></ref><ref id="B71-cancers-16-01594"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunikowska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morgenstern</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pe&#322;ka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bruchertseifer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kr&#243;licki</surname><given-names>L.</given-names></name></person-group><article-title>Targeted alpha therapy for glioblastoma</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><fpage>1085245</fpage><pub-id pub-id-type="doi">10.3389/fmed.2022.1085245</pub-id><pub-id pub-id-type="pmid">36590948</pub-id><pub-id pub-id-type="pmcid">PMC9800503</pub-id></element-citation></ref><ref id="B72-cancers-16-01594"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madsen</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Therkelsen</surname><given-names>A.S.N.</given-names></name><name name-style="western"><surname>Langkj&#230;r</surname><given-names>N.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Thisgaard</surname><given-names>H.</given-names></name></person-group><article-title>Auger electron therapy of glioblastoma using [(125)I]5-iodo-2&#8242;-deoxyuridine and concomitant chemotherapy&#8212;Evaluation of a potential treatment strategy</article-title><source>Nucl. Med. Biol.</source><year>2021</year><volume>96&#8211;97</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2021.03.001</pub-id><pub-id pub-id-type="pmid">33784592</pub-id></element-citation></ref><ref id="B73-cancers-16-01594"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasciak</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Manupipatpong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Gainsburg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krimins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zink</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Brayton</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sage</surname><given-names>J.</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>D.R.</given-names></name><etal/></person-group><article-title>Yttrium-90 radioembolization as a possible new treatment for brain cancer: Proof of concept and safety analysis in a canine model</article-title><source>EJNMMI Res.</source><year>2020</year><volume>10</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/s13550-020-00679-1</pub-id><pub-id pub-id-type="pmid">32804262</pub-id><pub-id pub-id-type="pmcid">PMC7431501</pub-id></element-citation></ref><ref id="B74-cancers-16-01594"><label>74.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food &amp; Drug Administration, Center for Devices and Radiological Health</collab></person-group><article-title>TheraSphere Y-90 Glass Microspheres Approval Letter. 17 March 2021</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029A.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029A.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-09">(accessed on 9 April 2024)</date-in-citation></element-citation></ref><ref id="B75-cancers-16-01594"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sofou</surname><given-names>S.</given-names></name></person-group><article-title>Radionuclide carriers for targeting of cancer</article-title><source>Int. J. Nanomed.</source><year>2008</year><volume>3</volume><fpage>181</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.2147/IJN.S2736</pub-id><pub-id pub-id-type="pmid">18686778</pub-id><pub-id pub-id-type="pmcid">PMC2527672</pub-id></element-citation></ref><ref id="B76-cancers-16-01594"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Ros</surname><given-names>V.</given-names></name><name name-style="western"><surname>Oddo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Toumia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guida</surname><given-names>E.</given-names></name><name name-style="western"><surname>Minosse</surname><given-names>S.</given-names></name><name name-style="western"><surname>Strigari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Strolin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paolani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Giuliano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Floris</surname><given-names>R.</given-names></name><etal/></person-group><article-title>PVA-Microbubbles as a Radioembolization Platform: Formulation and the In Vitro Proof of Concept</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15010217</pub-id><pub-id pub-id-type="pmid">36678846</pub-id><pub-id pub-id-type="pmcid">PMC9862136</pub-id></element-citation></ref><ref id="B77-cancers-16-01594"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foreman</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Cassady</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Markert</surname><given-names>J.M.</given-names></name></person-group><article-title>Oncolytic Virotherapy for the Treatment of Malignant Glioma</article-title><source>Neurotherapeutics</source><year>2017</year><volume>14</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1007/s13311-017-0516-0</pub-id><pub-id pub-id-type="pmid">28265902</pub-id><pub-id pub-id-type="pmcid">PMC5398989</pub-id></element-citation></ref><ref id="B78-cancers-16-01594"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiyokawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wakimoto</surname><given-names>H.</given-names></name></person-group><article-title>Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma</article-title><source>Oncolytic Virother.</source><year>2019</year><volume>8</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.2147/OV.S196403</pub-id><pub-id pub-id-type="pmid">31750274</pub-id><pub-id pub-id-type="pmcid">PMC6817710</pub-id></element-citation></ref><ref id="B79-cancers-16-01594"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zadeh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Daras</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cloughesy</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Colman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kumthekar</surname><given-names>P.U.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Aiken</surname><given-names>R.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramakrishna</surname><given-names>R.</given-names></name><etal/></person-group><article-title>LTBK-04. Phase 2 multicenter study of the oncolytic adenovirus dnx-2401 (tasadenoturev) in combination with pembrolizumab for recurrent glioblastoma; captive study (keynote-192)</article-title><source>Neuro Oncol.</source><year>2020</year><volume>22</volume><fpage>ii237</fpage><pub-id pub-id-type="doi">10.1093/neuonc/noaa215.989</pub-id></element-citation></ref><ref id="B80-cancers-16-01594"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gomez-Manzano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yung</surname><given-names>W.K.A.</given-names></name><name name-style="western"><surname>Sawaya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Prabhu</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Aldape</surname><given-names>K.D.</given-names></name><etal/></person-group><article-title>Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>1419</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.75.8219</pub-id><pub-id pub-id-type="pmid">29432077</pub-id><pub-id pub-id-type="pmcid">PMC6075856</pub-id></element-citation></ref><ref id="B81-cancers-16-01594"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gomez-Manzano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rivera-Molina</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Fueyo</surname><given-names>J.</given-names></name></person-group><article-title>Oncolytic adenovirus research evolution: From cell-cycle checkpoints to immune checkpoints</article-title><source>Curr. Opin. Virol.</source><year>2015</year><volume>13</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2015.03.009</pub-id><pub-id pub-id-type="pmid">25863716</pub-id><pub-id pub-id-type="pmcid">PMC4550502</pub-id></element-citation></ref><ref id="B82-cancers-16-01594"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bielamowicz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koss</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name></person-group><article-title>CAR-T Therapies in Solid Tumors: Opportunities and Challenges</article-title><source>Curr. Oncol. Rep.</source><year>2023</year><volume>25</volume><fpage>479</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1007/s11912-023-01380-x</pub-id><pub-id pub-id-type="pmid">36853475</pub-id><pub-id pub-id-type="pmcid">PMC10110629</pub-id></element-citation></ref><ref id="B83-cancers-16-01594"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jussing</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sam&#233;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grankvist</surname><given-names>R.</given-names></name><name name-style="western"><surname>Damberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dodoo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maeurer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Safety of Intra-Arterial Injection With Tumor-Activated T Cells to the Rabbit Brain Evaluated by MRI and SPECT/CT</article-title><source>Cell Transplant.</source><year>2017</year><volume>26</volume><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.3727/096368916X693347</pub-id><pub-id pub-id-type="pmid">27725029</pub-id><pub-id pub-id-type="pmcid">PMC5657767</pub-id></element-citation></ref><ref id="B84-cancers-16-01594"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Gumin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ledbetter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huse</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Development of a Rabbit Human Glioblastoma Model for Testing of Endovascular Selective Intra-Arterial Infusion (ESIA) of Novel Stem Cell-Based Therapeutics</article-title><source>Neuro Oncol.</source><year>2023</year><volume>26</volume><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noad152</pub-id><pub-id pub-id-type="pmid">37603323</pub-id><pub-id pub-id-type="pmcid">PMC10768973</pub-id></element-citation></ref><ref id="B85-cancers-16-01594"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chiocca</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity</article-title><source>Nat. Cancer</source><year>2022</year><volume>3</volume><fpage>1318</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00448-0</pub-id><pub-id pub-id-type="pmid">36357700</pub-id><pub-id pub-id-type="pmcid">PMC10150871</pub-id></element-citation></ref><ref id="B86-cancers-16-01594"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Todo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ohtsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shibahara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>M.</given-names></name></person-group><article-title>Intratumoral oncolytic herpes virus G47&#8710; for residual or recurrent glioblastoma: A phase 2 trial</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1630</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01897-x</pub-id><pub-id pub-id-type="pmid">35864254</pub-id><pub-id pub-id-type="pmcid">PMC9388376</pub-id></element-citation></ref><ref id="B87-cancers-16-01594"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>B.</given-names></name><etal/></person-group><article-title>CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma</article-title><source>Mol. Ther.</source><year>2023</year><volume>31</volume><fpage>134</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2022.08.021</pub-id><pub-id pub-id-type="pmid">36056553</pub-id><pub-id pub-id-type="pmcid">PMC9840126</pub-id></element-citation></ref><ref id="B88-cancers-16-01594"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>K.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>K.</given-names></name><name name-style="western"><surname>Meylan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bougo&#252;in</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salvucci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bielle</surname><given-names>F.</given-names></name><name name-style="western"><surname>O&#8217;Farrell</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bergers</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: Implications for precision immunotherapy</article-title><source>Ann. Oncol.</source><year>2023</year><volume>34</volume><fpage>300</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.11.008</pub-id><pub-id pub-id-type="pmid">36494005</pub-id></element-citation></ref><ref id="B89-cancers-16-01594"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.F.</given-names></name></person-group><article-title>Oncolytic Zika Virus: New Option for Glioblastoma Treatment</article-title><source>DNA Cell Biol.</source><year>2023</year><volume>42</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1089/dna.2022.0375</pub-id><pub-id pub-id-type="pmid">36350682</pub-id></element-citation></ref><ref id="B90-cancers-16-01594"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmadany</surname><given-names>N.</given-names></name><name name-style="western"><surname>Alhalabi</surname><given-names>O.T.</given-names></name><name name-style="western"><surname>Platten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bunse</surname><given-names>L.</given-names></name></person-group><article-title>Site-Specific Considerations on Engineered T Cells for Malignant Gliomas</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>1738</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10071738</pub-id><pub-id pub-id-type="pmid">35885047</pub-id><pub-id pub-id-type="pmcid">PMC9312945</pub-id></element-citation></ref><ref id="B91-cancers-16-01594"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blanzy</surname><given-names>J.</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>K.J.R.</given-names></name><name name-style="western"><surname>Preul</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Vernon</surname><given-names>B.L.</given-names></name></person-group><article-title>Liquid Embolic Agents for Endovascular Embolization: A Review</article-title><source>Gels</source><year>2023</year><volume>9</volume><elocation-id>378</elocation-id><pub-id pub-id-type="doi">10.3390/gels9050378</pub-id><pub-id pub-id-type="pmid">37232970</pub-id><pub-id pub-id-type="pmcid">PMC10217684</pub-id></element-citation></ref><ref id="B92-cancers-16-01594"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fujinami</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mase</surname><given-names>M.</given-names></name></person-group><article-title>Minimally invasive treatment for glioblastoma through endoscopic surgery including tumor embolization when necessary: A technical note</article-title><source>Front. Neurol.</source><year>2023</year><volume>14</volume><fpage>1170045</fpage><pub-id pub-id-type="doi">10.3389/fneur.2023.1170045</pub-id><pub-id pub-id-type="pmid">37153685</pub-id><pub-id pub-id-type="pmcid">PMC10160401</pub-id></element-citation></ref><ref id="B93-cancers-16-01594"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Curr&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tommasi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Sarno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Doddato</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baldassarri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frullanti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giliberti</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Fallerini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Spinazzola</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cell-free DNA next-generation sequencing liquid biopsy as a new revolutionary approach for arteriovenous malformation</article-title><source>JVS Vasc. Sci.</source><year>2020</year><volume>1</volume><fpage>176</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.jvssci.2020.08.002</pub-id><pub-id pub-id-type="pmid">34617046</pub-id><pub-id pub-id-type="pmcid">PMC8489236</pub-id></element-citation></ref><ref id="B94-cancers-16-01594"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>di Blasio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Curr&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monica</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sarno</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Doddato</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baldassarri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frullanti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giliberti</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome</article-title><source>Vascular</source><year>2021</year><volume>29</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1177/1708538120936421</pub-id><pub-id pub-id-type="pmid">32588787</pub-id></element-citation></ref><ref id="B95-cancers-16-01594"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cavaliere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rushing</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geraldo</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Belitzky</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rossano</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma</article-title><source>Sci. Transl. Med.</source><year>2023</year><volume>15</volume><fpage>eadi1617</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adi1617</pub-id><pub-id pub-id-type="pmid">37910601</pub-id><pub-id pub-id-type="pmcid">PMC11078331</pub-id></element-citation></ref><ref id="B96-cancers-16-01594"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rainov</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chase</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kramm</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Chiocca</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Weissleder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Breakefield</surname><given-names>X.O.</given-names></name></person-group><article-title>Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms</article-title><source>Hum. Gene Ther.</source><year>1995</year><volume>6</volume><fpage>1543</fpage><lpage>1552</lpage><pub-id pub-id-type="doi">10.1089/hum.1995.6.12-1543</pub-id><pub-id pub-id-type="pmid">8664379</pub-id></element-citation></ref><ref id="B97-cancers-16-01594"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baboota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>J.</given-names></name></person-group><article-title>Ligand conjugation: An emerging platform for enhanced brain drug delivery</article-title><source>Brain Res. Bull.</source><year>2018</year><volume>142</volume><fpage>384</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2018.08.003</pub-id><pub-id pub-id-type="pmid">30086350</pub-id></element-citation></ref><ref id="B98-cancers-16-01594"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>The blood-brain barrier: Structure, regulation, and drug delivery</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01481-w</pub-id><pub-id pub-id-type="pmid">37231000</pub-id><pub-id pub-id-type="pmcid">PMC10212980</pub-id></element-citation></ref><ref id="B99-cancers-16-01594"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name></person-group><article-title>Novel Nano-Drug Delivery System for Brain Tumor Treatment</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>3761</elocation-id><pub-id pub-id-type="doi">10.3390/cells11233761</pub-id><pub-id pub-id-type="pmid">36497021</pub-id><pub-id pub-id-type="pmcid">PMC9737081</pub-id></element-citation></ref><ref id="B100-cancers-16-01594"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boltze</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Strategies for Improved Intra-arterial Treatments Targeting Brain Tumors: A Systematic Review</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><fpage>1443</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.01443</pub-id><pub-id pub-id-type="pmid">32983974</pub-id><pub-id pub-id-type="pmcid">PMC7479245</pub-id></element-citation></ref><ref id="B101-cancers-16-01594"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rechberger</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>F.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>D.J.</given-names></name></person-group><article-title>Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1885</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13111885</pub-id><pub-id pub-id-type="pmid">34834300</pub-id><pub-id pub-id-type="pmcid">PMC8625566</pub-id></element-citation></ref><ref id="B102-cancers-16-01594"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoudi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Garvey</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bouras</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stepp</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jesu Raj</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Bozec</surname><given-names>D.</given-names></name><name name-style="western"><surname>Busch</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hadjipanayis</surname><given-names>C.G.</given-names></name></person-group><article-title>5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas</article-title><source>J. Neuro-Oncol.</source><year>2019</year><volume>141</volume><fpage>595</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1007/s11060-019-03103-4</pub-id><pub-id pub-id-type="pmid">30659522</pub-id><pub-id pub-id-type="pmcid">PMC6538286</pub-id></element-citation></ref><ref id="B103-cancers-16-01594"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death</article-title><source>Cancer Lett.</source><year>2023</year><volume>554</volume><fpage>216032</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2022.216032</pub-id><pub-id pub-id-type="pmid">36493899</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="cancers-16-01594-f001" orientation="portrait"><label>Figure 1</label><caption><p>Overview of advantages and limitations of super-selective cerebral arterial infusion (SSIACI) for high-grade gliomas (HGGs). Advantages of this technique include the ability to directly deliver high doses of drugs locally to the tumor bed due to decreased systemic effects with local endovascular drug delivery. Direct endovascular delivery may allow for additional ways to mitigate the BBB through concomitant administration of BBB disruptors such as focused ultrasound. However, off-target effects or thromboembolic events may be complications of endovascular procedures that can cause adverse patient events. Furthermore, normal cerebral blood flow can cause drug washout and decrease the local delivery of therapeutic drugs. The advantages and disadvantages of selective cerebral arterial infusion or endovascular drug delivery to the tumor bed should be considered when designing new therapeutic paradigms.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancers-16-01594-g001.jpg"/></fig><fig position="float" id="cancers-16-01594-f002" orientation="portrait"><label>Figure 2</label><caption><p>Multiple therapeutic drugs and treatments may be delivered endovascularly. Super-selective cerebral arterial infusion of chemotherapeutics, such as methotrexate, vincristine, diaziquone, etoposide, idarubicin, and bevacizumab, has been trialed for high-grade gliomas. Radionuclides, such as radioactive yttrium-90, can be delivered endovascularly on microbeads or with PVA microbubbles. Oncolytic viruses and CAR-T cells may also be delivered directly to the tumor or tumor bed endovascularly. Traditional endovascular techniques, including embolization with liquid embolics, remains a potential adjuvant option to increase tumor residence time of delivered drugs or decrease tumoral blood supply.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancers-16-01594-g002.jpg"/></fig><table-wrap position="float" id="cancers-16-01594-t001" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01594-t001_Table 1</object-id><label>Table 1</label><caption><p>Ongoing trials of super-selective intra-arterial cerebral infusion are listed, along with the treatment used, the study type, patient cohort, and outcomes measured.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient Cohort</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02285959">NCT02285959</ext-link> <break/>Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme&#8221;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bevacizumab repeated every 3 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I single-arm prospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent GBM after resection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Adverse events Secondary: Tumor response</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02861898">NCT02861898</ext-link> <break/>Super-Selective Intra-Arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma&#8221;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab and Mannitol for 3 doses q3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I/II single-arm prospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Newly diagnosed GBM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Progression-free survival at 6 months and overall survival at 2 years<break/>Secondary: Composite overall response rate and toxicity by CTCAE</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05271240">NCT05271240</ext-link> <break/>Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab with Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM&#8221;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bevacizumab and mannitol + Temozolomide and XRT 3 doses q3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III randomized control trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Newly diagnosed GBM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Overall survival Secondary: Progression-free survival </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01269853">NCT01269853</ext-link> <break/>Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA&#8221;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bevacizumab and mannitol q2 week +/&#8722; IV bevacizumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I/II two-arm non-randomized prospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent GBM and anaplastic astrocytoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Composite overall response; progression-free survival and overall survival at 6 months<break/>Secondary: Toxicity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05773326">NCT05773326</ext-link> <break/>Superselective Intra-Arterial Cerebral Infusion of Temsirolimus in HGG&#8221;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Temsirolimus single infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 0 single-arm prospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Newly diagnosed GBM pre-operatively</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Total and unbound temsirolimus in tumor tissue<break/>Secondary: Quantification of pS6 positive cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02800486">NCT02800486</ext-link> <break/>Super Selective Intra-Arterial Repeated Infusion of Cetuximab (Erbitux) with Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA&#8221;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab with mannitol and radiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II prospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Relapsed/refractory GBM, AA, AOA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: PFS at 6 months and OS at 2 years<break/>Secondary: CORR and toxicity via CTCAE</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05956821">NCT05956821</ext-link> <break/>Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age&#8221;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab and bevacizumab q1 month for 1 year</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I/II prospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent GBM &lt; 22 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Adverse events, CORR, and PFS and OS at 1 year</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03896568">NCT03896568</ext-link> <break/>MSC-DNX-2401 in Treating Patients with Recurrent High-Grade Glioma&#8221;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSC-DNX-2401 oncolytic adenovirus 1&#8211;2 infusions 2 weeks pre-op + intramural injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I prospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent GBM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Max tolerated dose and adverse events<break/>Secondary: Tumor response, time to progression, virus replication in tumor, virus shedding, and adenoviral antibodies</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>